Lorena Diéguez
CEO
Ruby Nanomed
Ruby Nanomed develops a microfluidic liquid biopsy device that analyzes circulating tumor cells and biomarkers in blood samples for early cancer detection. This technology provides clinicians with precise insights to inform personalized treatment decisions, ultimately enhancing patient outcomes.
- Biotechnology
- Healthcare Technology
- Medical Devices
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Current methods for monitoring cancer progression often involve invasive procedures, such as tissue biopsies, which can be costly, time-consuming, and pose risks to patients. The need for frequent monitoring to assess treatment effectiveness and detect recurrence presents a challenge due to the limitations of traditional biopsy methods. This creates a demand for non-invasive, real-time monitoring tools that can provide comprehensive insights into a patient's cancer status.
Solution
RUBYnanomed offers the RUBYchip™, a microfluidic liquid biopsy device designed for non-invasive cancer monitoring. This technology analyzes circulating tumor cells (CTCs) and other biomarkers in blood samples, providing a comprehensive cancer snapshot. The RUBYchip™ enables oncologists to monitor cancer progression in real-time, facilitating timely and informed treatment decisions. By eliminating the need for sample preparation and offering higher selectivity and sensitivity, the RUBYchip™ provides a cost-effective solution for frequent cancer monitoring. The device's ability to deliver earlier diagnoses through non-invasive analysis enhances patient outcomes by enabling personalized treatment strategies.
Target Audience
The primary target audience includes oncologists and clinical partners seeking non-invasive, real-time tools for monitoring cancer progression and making informed treatment decisions.
Features
- Microfluidic technology for analyzing circulating tumor cells (CTCs) and biomarkers in liquid biopsies
- Non-invasive cancer monitoring, reducing patient risk and discomfort
- Real-time monitoring of cancer progression for timely treatment adjustments
- Higher selectivity and sensitivity for accurate detection of cancer biomarkers
- Cost-effective solution compared to traditional biopsy methods
- No sample preparation required, streamlining the analysis process